Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure

• Type: Another Publication in an International Scientific Journal
• Date: 2023

Authors

Ferreira, JP (Author) FMUP; Sharma, A (Author) Other; Butler, J (Author) Other; Packer, M (Author) Other; Zannad, F (Author) Other; Vasques Nóvoa, F (Author) FMUP; Leite-Moreira AF (Author) FMUP; Neves, JS (Author) FMUP

Journal

Title: Journal of Clinical Endocrinology and Metabolism

Vol. 109

Pages: 4-9

ISSN: 0021-972X

Publisher: Endocrine Society

Indexing

ISI Web of Knowledge - 5 Citations

Scopus - 4 Citations

Other information

Authenticus ID: P-00Y-TGC

DOI: 10.1210/clinem/dgad398

Abstract (EN): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RAs may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across a patient's risk with a particular focus on HF. After a careful review of the literature, we challenge the current views about the use of GLP-1 RAs and suggest performing active HF screening (with directed clinical history, physical examination, an echocardiogram, and natriuretic peptides) before initiating a GLP-1 RA. After HF screening, we suggest GLP-1 RA treatment decisions as follows: (1) in people with T2D without HF, GLP-1 RAs should be used for reducing the risk of myocardial infarction and stroke, with a possible effect to reduce the risk of HF hospitalizations; (2) in patients with HF and preserved ejection fraction, GLP-1 RAs do not reduce HF hospitalizations but may reduce atherosclerotic events, and their use may be considered in an individualized manner; and (3) in patients with HF and reduced ejection fraction, the use of GLP-1 RAs warrants caution due to potential risk of worsening HF events and arrhythmias, pending risk-benefit data from further studies.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6